Skip to main content
SpringerLink
Log in

Glykoprotein-IIb/IIIa-Hemmer und ADP-Antagonisten

  • Conference paper
Gerinnungsaktive Therapie beim akuten Koronarsyndrom

  • 20 Accesses

Zusammenfassung

Zelluläre Hämostase und plasmatische Gerinnung sind funktionell eng miteinander verbunden (Abb. 1). So exponieren aktivierte Plättchen an ihrer Oberfläche prokoagulatorische Aktivität, die die Thrombin-und anschließende Fibrinbildung verstärkt. Thrombin ist nicht nur das Schlüsselenzym der plasmatischen Gerinnung, sondern auch ein äußerst potenter Plättchenstimulator, wobei zur Plättchenstimulation weniger als 1/10 der Thrombinkonzentration genügt, die zur Gerinnung führt. Das bedeutet zum einen, daß immer dann, wenn es zur Gerinnung kommt, auch Plättchen aktiviert werden. Andererseits kann in Gegenwart eines Thrombinhemmstoffes, wie z. B. Hirudin, auch bei einer starken Gerinnungshemmung noch genügend Thrombin entstehen, um Plättchen zu aktivieren und die zelluläre Hämostase sicherzustellen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Charo IF, Kieffer N, Phillips DR (1994) Platelet membrane glycoproteins. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice, 3rd edn. Lippincott, Philadelphia, p 489

    Google Scholar 

  2. Coukell AJ, Markham A (1997) Clopidogrel. Drugs 54: 745–751

    Article  CAS  Google Scholar 

  3. Dyken ML (1998) Antiplatelet agents and stroke prevention. Semin Neurol 18: 441–450

    Article  PubMed  CAS  Google Scholar 

  4. Gawaz M, Ruf A, Neumann F-J, Pogâtsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A (1998) Effect of glycoprotein IIb/IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 80: 994–1001

    PubMed  CAS  Google Scholar 

  5. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P (1998) The antiaggregating and anti-thrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 80: 512–518

    PubMed  CAS  Google Scholar 

  6. Jennings LK, White MM (1998) Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J 135: S179–183

    Article  Google Scholar 

  7. Mascelli MA, Worley S, Veriabo NJ et al. (1997) Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy. Circulation 96: 3860–3866

    PubMed  CAS  Google Scholar 

  8. Misson J, Clark W, Kendall MJ (1998) Clopidogrel: secondary prevention of vascular ischaemic events. J Clin Pharm Ther 23: 91–95

    PubMed  CAS  Google Scholar 

  9. Moroi M, Jung SM (1997) Platelet receptors for collagen. Thromb Haemost 78: 439–444

    PubMed  CAS  Google Scholar 

  10. Peter K, Schwarz M, Ylanne J et al. (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphallbbeta3) inhibitors. Blood 92: 3240–3249

    PubMed  CAS  Google Scholar 

  11. Schömig A, Neumann FJ, Kastrati A et al. (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334: 1084–1089

    Article  PubMed  Google Scholar 

  12. Sharis PJ, Cannon CP, Loscalzo (1998) The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 129: 394–405

    PubMed  CAS  Google Scholar 

  13. Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998) Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 98: 1085–1091

    PubMed  CAS  Google Scholar 

  14. Tcheng JE, Ellis SG, George BS et al. (1994) Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90: 1757–1764

    PubMed  CAS  Google Scholar 

  15. Thizon-de-Gaulle I (1998) Antiplatelet drugs in secondary prevention after acute myocardial infarction. Rev Port Cardiol 17: 993–997

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. Patscheke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Gefäßmedizin Frankfurt, Zeil 51, D-60313, Frankfurt/Main, Deutschland

    Viola Hach-Wunderle

  2. Abteilung Innere Medizin, Klinikum Kassel, Mönchebergstr. 41–43, D-34125, Kassel, Deutschland

    Karl-Ludwig Neuhaus

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Patscheke, H. (2000). Glykoprotein-IIb/IIIa-Hemmer und ADP-Antagonisten. In: Hach-Wunderle, V., Neuhaus, KL. (eds) Gerinnungsaktive Therapie beim akuten Koronarsyndrom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59667-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59667-4_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-66379-9

  • Online ISBN: 978-3-642-59667-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation